Denver– Cleerly, a leader in AI-driven cardiovascular imaging, has entered a strategic partnership with Cardiac Care Alliance to integrate advanced diagnostic technology into value-based heart care, aiming to reduce unnecessary procedures and improve patient outcomes through earlier, more accurate detection of coronary artery disease.
The collaboration will combine Cleerly’s AI-QCT (Artificial Intelligence–Quantitative Coronary Tomography) platform with Cardiac Care Alliance’s national cardiovascular care network. The technology uses noninvasive cardiac CT angiography to assess the presence, extent, and type of atherosclerotic plaque with precision that studies have shown to outperform even expert physician consensus readings.
As part of the partnership, cardiology practices—beginning in Texas—will incorporate Cleerly’s AI-based imaging to identify patients who can benefit from cardiac catheterization, while helping avoid unnecessary invasive procedures and the costs that come with them. Broader national rollout is planned.
“This partnership is about delivering smarter, more cost-effective care,” said Dr. Prakash Patel, CEO and Chairman of Cardiac Care Alliance. “Cardiovascular disease costs the U.S. more than $230 billion annually and accounts for 11% of total healthcare spending. By better identifying who truly needs intervention, we can improve care and reduce the strain on the system.”
Cardiac Care Alliance specializes in building networks that connect cardiologists, primary care providers, health systems, and insurers to offer comprehensive, efficient cardiovascular care under value-based care models. Cleerly’s technology adds a high-accuracy, standardized tool to the diagnostic workflow that can support earlier interventions and more targeted treatment plans.
“This marks Cleerly’s first partnership in value-based care and an important step in our mission to transform how we detect and treat heart disease,” said Dr. James Min, founder and CEO of Cleerly. “Many cardiac conditions are treatable when caught early. With healthcare costs projected to exceed $1 trillion by 2035 and readmissions for cardiac conditions among Medicare’s most expensive issues, we believe integrating precision diagnostics into frontline care is critical.”
The partnership reflects a growing movement in U.S. healthcare to shift away from reactive, procedure-driven care toward proactive, data-informed approaches that emphasize prevention, personalized treatment, and cost control—particularly in high-impact areas like cardiovascular health.
